Rwanda Biomedical Center

Rwanda Biomedical Center, operating as National Assembly of Rwanda, is a foreign government entity based in Kigali, Rwanda, that serves as a grant recipient for the Centers for Disease Control and Prevention (CDC) under the President's Emergency Plan for AIDS Relief (PEPFAR), implementing HIV prevention, care, and treatment services in Rwanda. The organization operates primarily as a prime grant recipient (75% of recent awards) and secondarily as a sub-recipient on food security and health programs.

Rwanda Biomedical Center's federal footprint centers on two primary cooperative agreements awarded by the CDC's Center for Global Health on September 30, 2024, and running through September 29, 2029. The first cooperative agreement, "Strengthening HIV Clinical Services in the Republic of Rwanda Under PEPFAR," funds evidence-based HIV prevention and care interventions targeting viral load suppression for people living with HIV across Rwanda. The second, "Implementing Technical and Science Support Services (TSSS) in the Republic of Rwanda Under PEPFAR," supports technical leadership, quality improvement for HIV laboratory services, and strategic information systems for integrated service delivery and surveillance. Combined, these two awards carry obligated federal funding totaling roughly $148.1 million across twelve awards in the source data spanning nearly two decades.

Customer concentration is narrow. The CDC accounts for nine of twelve awards (75% of recent activity), while the Department of Agriculture's Foreign Agricultural Service Food for Education program anchors three awards. Rwanda Biomedical Center also serves as a sub-recipient under United Nations World Food Programme cooperative agreements, implementing deworming, water, and sanitation programs with a sub-award dated October 1, 2025, and extending through December 2025. Award activity has accelerated recently — three awards in 2024 compared to one in 2019 and one in 2016 — though the organization's heavy concentration on CDC PEPFAR funding and its status as a foreign government entity limit its relevance to most U.S. federal contractor competitive dynamics.